| Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions J Rosenblatt, RM Stone, L Uhl, D Neuberg, R Joyce, JD Levine, ... Science translational medicine 8 (368), 368ra171-368ra171, 2016 | 188 | 2016 |
| MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia AR Pyzer, D Stroopinsky, H Rajabi, A Washington, A Tagde, M Coll, ... Blood, The Journal of the American Society of Hematology 129 (13), 1791-1801, 2017 | 165 | 2017 |
| CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma JA Harris, S Jain, Q Ren, A Zarineh, C Liu, S Ibrahim Diagnostic pathology 7, 1-6, 2012 | 106 | 2012 |
| Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma S Jain, C Diefenbach, J Zain, OA O’Connor Core evidence, 43-57, 2011 | 80 | 2011 |
| MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs AR Pyzer, D Stroopinsky, J Rosenblatt, E Anastasiadou, H Rajabi, ... Leukemia 31 (12), 2780-2790, 2017 | 69 | 2017 |
| Romidepsin in the treatment of cutaneous T-cell lymphoma S Jain, J Zain Journal of blood medicine, 37-47, 2011 | 67 | 2011 |
| Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas S Jain, A Van Scoyk, EA Morgan, A Matthews, K Stevenson, G Newton, ... Blood, The Journal of the American Society of Hematology 134 (17), 1430-1440, 2019 | 65 | 2019 |
| Novel therapeutic agents for cutaneous T-Cell lymphoma S Jain, J Zain, O O’Connor Journal of hematology & oncology 5, 1-15, 2012 | 64 | 2012 |
| Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine MR Nahas, D Stroopinsky, J Rosenblatt, L Cole, AR Pyzer, ... British journal of haematology 185 (4), 679-690, 2019 | 62 | 2019 |
| Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma S Jain, X Jirau-Serrano, KM Zullo, L Scotto, CF Palermo, SA Sastra, ... Clinical Cancer Research 21 (9), 2096-2106, 2015 | 62 | 2015 |
| Preclinical models of cancer therapy–associated cardiovascular toxicity: a scientific statement from the American heart association A Asnani, JJ Moslehi, BB Adhikari, AH Baik, AM Beyer, RA de Boer, ... Circulation research 129 (1), e21-e34, 2021 | 57 | 2021 |
| Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma S Jain, D Stroopinsky, L Yin, J Rosenblatt, M Alam, P Bhargava, RA Clark, ... Blood, The Journal of the American Society of Hematology 126 (3), 354-362, 2015 | 45 | 2015 |
| Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease MR Nahas, RJ Soiffer, HT Kim, EP Alyea III, J Arnason, R Joyce, JH Antin, ... Blood, The Journal of the American Society of Hematology 131 (25), 2836-2845, 2018 | 39 | 2018 |
| Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: results from the comprehensive oncology measures for peripheral T‐cell lymphoma … RN Stuver, N Khan, M Schwartz, M Acosta, M Federico, C Gisselbrecht, ... American journal of hematology 94 (6), 641-649, 2019 | 38 | 2019 |
| Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC 1 M Bar‐Natan, D Stroopinsky, K Luptakova, MD Coll, A Apel, H Rajabi, ... British journal of haematology 176 (6), 929-938, 2017 | 32 | 2017 |
| Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1 W Wu, GM Nelson, R Koch, KA Donovan, RP Nowak, TB Heavican-Foral, ... Blood, The Journal of the American Society of Hematology 139 (13), 2024-2037, 2022 | 20 | 2022 |
| FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a … A Raphael, E Dudnik, D Hershkovitz, S Jain, S Olsen, L Soussan-Gutman, ... Journal of Clinical Medicine 11 (9), 2475, 2022 | 18 | 2022 |
| MUC 1‐C drives myeloid leukaemogenesis and resistance to treatment by a survivin‐mediated mechanism D Stroopinsky, H Rajabi, M Nahas, J Rosenblatt, M Rahimian, A Pyzer, ... Journal of cellular and molecular medicine 22 (8), 3887-3898, 2018 | 18 | 2018 |
| DCOne as an allogeneic cell-based vaccine for multiple myeloma RK Leaf, D Stroopinsky, AR Pyzer, AM Kruisbeek, S van Wetering, ... Journal of Immunotherapy 40 (9), 315-322, 2017 | 18 | 2017 |
| Decitabine priming enhances mucin 1 inhibition mediated disruption of redox homeostasis in cutaneous T-cell lymphoma S Jain, A Washington, RK Leaf, P Bhargava, RA Clark, TS Kupper, ... Molecular cancer therapeutics 16 (10), 2304-2314, 2017 | 17 | 2017 |
